TechSeeker Profile

Agenus Inc (AKA:Antigenics Inc)
Profile last edited on: 9/15/2014

focused on the development and commercialization of technologies to treat cancers and infectious diseases
TS Type
N/A
Status
Year Founded
1994
Last Involved Year
2013

Key People / Management

  Garo H Armen -- President

  Christine M Klaskin -- Principal Financial Officer, Principal Accounting Officer and VP of Fin.

  Marcel Rozencweig -- Acting Chief Medical Officer

  Karen H Valentine -- Vice President, Chief Compliance Officer, General Counsel, Secretary

Location Information

3 Forbes Road
Lexington, MA 02421-730
   781-674-4400
   www.antigenics.com

Public Profile

Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies. The company offers Oncophage vaccine for the treatment of renal cell carcinoma in patients at intermediate risk of recurrence. Its products under development include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of malaria, melanoma, non-small cell lung cancer, and shingles, as well as for the treatment of various infectious diseases, multiple cancer types, and Alzheimer?s disease; and HerpV, a therapeutic vaccine candidate that is in Phase 2 clinical trial for the treatment of genital herpes. The company?s products under development also comprise Prophage series of cancer vaccines, including R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its Prophage series of cancer vaccines were tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and are in Phase I and Phase II clinical trials for various indications, and in Phase II clinical trials for the treatment of diagnosed and recurrent glioma. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Headquartered
USA
Employment
114
Revenue
$0.0B
Public/Private
Publicly Traded
Stock Info
NASDAQ : AGEN
Received SBIR $$
No

SBIR firms in the news

There are no news available.